Bladder Cancer in 2010: How Far have We Come?
CA A Cancer Journal for Clinicians2010Vol. 60(4), pp. 244–272
Citations Over TimeTop 1% of 2010 papers
Abstract
Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.
Related Papers
- → Bladder preservation protocols in the management of muscle-invasive bladder cancer: A systematic review(2018)2 cited
- → Editorial comment: understanding the cost of bladder preservation in muscle invasive bladder cancer—an evaluation of radical cystectomy versus trimodal therapy costs(2019)1 cited
- Clinical study of partial cystectomy combined with chemotherapy for muscle-invasive bladder cancer(2012)
- → Chemo-radiation in Muscle Invasive Bladder Cancer(2021)
- → The Role of Palliative Cystectomy in Bladder Cancer(2021)